EDVA
Endovia Health Sciences, Inc.
There isn't enough reported data to score EDVA yet.
EDVA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
EDVA's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
EDVA PE Valuation
EDVA has no meaningful PE right now: it lost money over the past year.
EDVA Forward outlook
There aren't enough analyst estimates for EDVA to show an outlook.
EDVA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2024 | -$77.19 | -$1.47 |
| Q1 2024 | -$80.39 | -$0.74 |
| Q4 2023 | -$78.40 | +$12.84 |
| Q3 2021 | -$174.99 | -$154.19 |
| Q2 2021 | -$121.58 | -$107.18 |
| Q1 2021 | -$84.81 | -$70.41 |
| Q4 2020 | -$83.20 | -$76.80 |
| Q3 2020 | -$20.80 | -$19.00 |
EDVA is still losing money, but far less than before: $77.19 per share over the past year, against $174.99 at its worst in late 2021.
EDVA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $4.2K | -99% |
| Q1 2025 | $438.3K | -72% |
| Q4 2024 | $585.9K | -78% |
| Q3 2024 | $981.9K | -81% |
| Q2 2024 | $1M | -80% |
| Q1 2024 | $1.5M | -74% |
| Q4 2023 | $2.7M | -44% |
| Q3 2023 | $5.1M | +5.6% |
EDVA's revenue has slid since its 2023 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -23176% | -22078 points |
| Q1 2025 | -464% | -253 points |
| Q4 2024 | -1098% | -976 points |
| Q3 2024 | -272% | -188 points |
| Q2 2024 | -353% | -271 points |
| Q1 2024 | -211% | -152 points |
| Q4 2023 | -122% | -23 points |
| Q3 2023 | -84% | +21 points |
EDVA's operating margin was −23176% last quarter, down 22824 points from the same quarter a year ago, near the bottom of its range since 2019.
EDVA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.1M | -$411.4K |
| Q1 2026 | -$930.5K | -$206.4K |
| Q2 2025 | -$680.3K | +$1.7M |
| Q1 2025 | -$724.1K | +$583.8K |
| Q3 2024 | -$2.6M | -$663.7K |
| Q2 2024 | -$2.4M | -$9.8K |
| Q1 2024 | -$1.3M | +$2.8M |
| Q4 2023 | -$1.7M | +$1.8M |
EDVA has burned cash in almost every quarter: −$3M over the past year, against −$8M the year before.
EDVA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.6% | +27K shares |
| 1 year | +17% | +44.1K shares |
| 3 years | +80% | +136K shares |
EDVA has 306,974 diluted shares, up 17% from a year ago.
EDVA Net Leverage
EDVA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
EDVA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 7.9 | Oversold |
EDVA's weekly RSI is 31 (neutral) and its Stochastic is 8 (oversold).
EDVA PE vs Healthcare Sector
EDVA has no meaningful PE right now: it lost money over the past year.
EDVA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.17 | 5.9% below |
| 20 week MA | $0.30 | 47% below |
| 50 week MA | $1.40 | 89% below |
| 100 week MA | $8.44 | 98% below |
| 200 week MA | $55.4 | 100% below |
EDVA is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
EDVA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $524.8 | $190.4 | -64% |
| 2022 | $190.4 | $135.2 | -29% |
| 2023 | $135.2 | $88.4 | -35% |
| 2024 | $88.4 | $28.0 | -68% |
| 2025 | $28.0 | $3.85 | -86% |
| 2026 YTD | $3.85 | $0.16 | -96% |
EDVA has finished every year since 2021 lower, and it's down 96% so far in 2026.